- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03592472
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
January 22, 2024 updated by: Xynomic Pharmaceuticals, Inc.
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In this randomized, Phase 3, double-blind, placebo-controlled study, patients will be randomized 2:1 to receive either a combination of pazopanib plus abexinostat or pazopanib plus placebo.
At the time of disease progression, patient treatment assignment will be unblinded, and those patients randomized to the pazopanib plus placebo treatment arm will have the option of crossing over to receive treatment with a combination of pazopanib plus abexinostat.
After providing written informed consent, patients will be screened for study eligibility within 28 days before their first dose of study drug.
After screening assessments, patients who are eligible for inclusion in the study will be randomized and receive their first dose of study drug on Cycle 1 Day 1 (C1D1), within 7 days of randomization.
A treatment cycle is 28 days in length.
Patients may continue to receive study drug until any of the following events: the development of IRC-verified radiographic progression as assessed by RECIST version 1.1, clinical disease progression, unacceptable toxicity, another discontinuation criterion is met, withdrawal of consent, or closure of the study by the sponsor.
No maximum duration of therapy has been set.
Study Type
Interventional
Enrollment (Estimated)
413
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sophia Paspal, Ph.D.
- Phone Number: 6104055974
- Email: sophia.paspal@xynomicpharma.com
Study Contact Backup
- Name: Rahul Aggarwal, M.D.
- Email: rahul.aggarwal@ucsf.edu
Study Locations
-
-
-
Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Bixia Tang, MD, PhD
- Phone Number: 13810211044
- Email: bixiatang_med@126.com
-
Shanghai, China, 200032
- Not yet recruiting
- Zhongshan Hospital affiliated to Fudan University
-
Contact:
- Xiaoyi Hu, MD, PhD
- Phone Number: 13917166233
- Email: hu.xiaoyi@zs-hospital.sh.cn
-
-
-
-
-
Candiolo, Italy, 10060
- Withdrawn
- Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica
-
Catania, Italy, 95126
- Withdrawn
- A.O. Cannizzaro_UOS Oncologia Medica
-
Meldola (FC), Italy, 47014
- Withdrawn
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica
-
Milano, Italy, 20141
- Withdrawn
- Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale
-
Napoli, Italy, 80131
- Withdrawn
- Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica
-
Novara, Italy, 28100
- Withdrawn
- Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica
-
Pavia, Italy, 27100
- Withdrawn
- Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica
-
Pisa, Italy, 56126
- Withdrawn
- Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria
-
Roma, Italy, '00168
- Withdrawn
- Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica
-
-
-
-
-
Goyang-si, Korea, Republic of, 10408
- Completed
- National Cancer Center - Center For Prostate Cancer
-
Seongnam-si, Korea, Republic of, 13496
- Completed
- CHA Bundang Medical Center, CHA University
-
Seoul, Korea, Republic of, 03722
- Completed
- Severance Hospital, Yonsei University Health System - Medical Oncology
-
Seoul, Korea, Republic of, 05505
- Completed
- Asan Medical Center - University of Ulsan College of Medicin
-
Seoul, Korea, Republic of, 06351
- Withdrawn
- Samsung Medical Center - Hematology-Oncology
-
-
-
-
-
Brzozow, Poland, 36-200
- Withdrawn
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny
-
Gdynia, Poland, 81-519
- Withdrawn
- Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii
-
Krakow, Poland, 31-826
- Completed
- Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym
-
Poznan, Poland, 60-848
- Withdrawn
- Clinical Research Center Sp. z o.o., Medic-R Sp. K.
-
-
-
-
-
Elche, Spain, 03203
- Withdrawn
- H.G.U. de Elche
-
Madrid, Spain, 28041
- Completed
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28040
- Withdrawn
- Hospital Universitario Fundacion Jimenez Diaz
-
Málaga, Spain, 29010
- Withdrawn
- H.U. Virgen de la Victoria
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Withdrawn
- University Of UA Cancer Center(UACC)/DH-SJHMC
-
-
California
-
Sacramento, California, United States, 95817
- Withdrawn
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, United States, 94158
- Withdrawn
- UCSF Helen Diller Family Comphrensive Cancer Center - Hemato
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Completed
- Norton Cancer Institute, Norton Healthcare Pavilion
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Completed
- Ochsner Clinic Foundation
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Completed
- Nebraska Cancer Specialists
-
Omaha, Nebraska, United States, 68130
- Withdrawn
- GU Research Network/Urology Cancer Center
-
-
New York
-
Lake Success, New York, United States, 11042
- Withdrawn
- Northwell Health/Monter Cancer Center
-
Rochester, New York, United States, 14642
- Completed
- Mainstreet Physicans Care
-
-
Ohio
-
Kettering, Ohio, United States, 45409
- Withdrawn
- Precision Cancer Research/Dayton Physicians Network - Treatment
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Completed
- Oregon Health and Science University
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- Completed
- St. Luke's Hospital
-
-
Texas
-
Tyler, Texas, United States, 75701
- Completed
- HOPE Cancer Center of East Texas
-
-
Washington
-
Spokane, Washington, United States, 99208
- Withdrawn
- Medical Oncology Associates, PS (dba Summit Cancer Centers)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
To be enrolled in the study, patients will be required to meet all of the following criteria:
- Patients aged ≥ 18 years at time of study entry.
- Patients have histologically confirmed RCC with clear cell component.
- Patients have locally advanced and unresectable or metastatic disease.
- Measurable disease as assessed only by the investigator (not verified by IRC) according to RECIST version 1.1.
- Patients must not have had any prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally advanced/metastatic setting. Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment.
- Patients have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients have adequate baseline organ function.
- Patients have adequate baseline hematologic function
- Patient must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization.
Exclusion Criteria:
Patients who meet any of the following criteria at Screening will not be enrolled in the study:
- Has persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
- Has untreated central nervous system (CNS) metastases. Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated.
- Has an additional malignancy requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
- Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
- A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
- Has a QTcF interval > 480 msec.
- New York Heart Association Class III or IV congestive heart failure.
- Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pazopanib plus abexinostat
Randomized patients will receive a combination of pazopanib plus abexinostat.
The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart.
Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
|
All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle.
Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning.
Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal.
Patients should be instructed to swallow the tablets whole and not chew them.
Other Names:
The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart.
Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart.
Patients should be instructed to swallow the tablets whole and not chew them.
Other Names:
|
Placebo Comparator: Pazopanib plus placebo
Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo.
The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart.
Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
|
All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle.
Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning.
Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal.
Patients should be instructed to swallow the tablets whole and not chew them.
Other Names:
The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart.
Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart.
Patients should be instructed to swallow the tablets whole and not chew them.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
|
To compare the PFS between treatment arms.
PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by blinded Independent Review Committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS by investigator assessment according to RECIST version 1.1.
Time Frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
|
To compare the PFS between treatment arms by investigator assessment.
PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by IRC according to RECIST version 1.1.
|
From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
|
Overall survival (OS)
Time Frame: From progression or end of study, every 3 months follow up until death, patient withdrawal from study follow-up, or study closure, whichever occurs first (up to approximately 4 years).
|
OS is defined as the interval between date of randomization and date of death.
The main objective was to compare the OS between treatment arms by investigator assessment.
|
From progression or end of study, every 3 months follow up until death, patient withdrawal from study follow-up, or study closure, whichever occurs first (up to approximately 4 years).
|
Adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5
Time Frame: From Day 1 until end of treatment visit (up to approximately 4 years).
|
To characterize the safety profile of pazopanib in combination with abexinostat.
|
From Day 1 until end of treatment visit (up to approximately 4 years).
|
Objective response rate (ORR)
Time Frame: Screening, Cycle 3 Day 1 (C3D1), Cycle 5 Day 1 (C5D1), Cycle 7 Day 1 (C7D1), and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
ORR is defined as the proportion of patients with objective evidence of CR or PR by RECIST version 1.1.
The main objective was to compare the ORR between treatment arms by investigator assessment.
|
Screening, Cycle 3 Day 1 (C3D1), Cycle 5 Day 1 (C5D1), Cycle 7 Day 1 (C7D1), and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
Duration of response (DOR)
Time Frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
DOR is defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause by RECIST version 1.1.
The main objective was to compare the DOR between treatment arms by investigator assessment.
|
Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
ORR by RECIST version 1.1 in cross-over patient population
Time Frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
To describe the ORR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment.
|
Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
DOR by RECIST version 1.1 in cross-over patient population
Time Frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
To describe the DOR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment.
|
Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
|
Mean change from Baseline in Functional Assessment of Cancer Therapy Kidney System Index (FKSI-19) scores
Time Frame: First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) until end-of-treatment visit (up to approximately 4 years).
|
To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and health-related quality of life (QoL) by investigator assessment.
QoL will be assessed by measuring change from baseline in FKSI-19.
The FKSI-19 assesses disease-related symptoms experienced in the past 7 days.
Patients are asked to respond to 12 questions ("I have a lack of energy," "I feel pain," for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 48).
|
First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) until end-of-treatment visit (up to approximately 4 years).
|
Mean change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT-F) scores
Time Frame: First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) and at end-of-treatment visit (up to approximately 4 years).
|
To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and QoL by investigator assessment.
QoL will be assessed by measuring change from baseline in FACIT-F.
The FACIT-F scale measures QoL experienced in the past seven days.
The measurement consisted of 5 domains (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns) assessed on a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much).
|
First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) and at end-of-treatment visit (up to approximately 4 years).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Pamela Munster, M.D., University of California, San Francisco
- Study Chair: Rahul Aggarwal, M.D., University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2018
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
June 23, 2018
First Submitted That Met QC Criteria
July 9, 2018
First Posted (Actual)
July 19, 2018
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Histone Deacetylase Inhibitors
- Abexinostat
Other Study ID Numbers
- XYN-602
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on Pazopanib
-
Cure HHTUniversity of North CarolinaNot yet recruitingEpistaxis | Hereditary Hemorrhagic Telangiectasia
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedMetastatic Renal Cell Carcinoma
-
Institut Claudius RegaudNovartisTerminatedMetastatic Cancer (Different Solid Tumour Types)France
-
Gynecologic Oncology GroupGlaxoSmithKlineWithdrawnUterine Leiomyosarcoma
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Spanish Oncology Genito-Urinary GroupCompletedMetastatic Renal Cell CarcinomaSpain
-
GlaxoSmithKlineCompletedMacular DegenerationUnited States
-
Samsung Medical CenterCompletedLocally Advanced or Metastatic Non-clear Cell Type Renal Cell CarcinomaKorea, Republic of
-
Samsung Medical CenterCompletedNeuroendocrine TumorKorea, Republic of